Shopping Cart
- Remove All
- Your shopping cart is currently empty
PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $55 | In Stock | |
2 mg | $82 | In Stock | |
5 mg | $136 | In Stock | |
10 mg | $198 | In Stock | |
25 mg | $331 | In Stock | |
50 mg | $451 | In Stock | |
100 mg | $595 | In Stock | |
500 mg | $1,180 | In Stock | |
1 mL x 10 mM (in DMSO) | $151 | In Stock |
Description | PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model. |
In vitro | PD-1/PD-L1-IN-9 (46.9-1500 nM; pretreated for 2 h) enhances the antitumor immunity of PBMCs against MDB-MB 231 cells in a dose-dependent manner, with an EC50 of approximately 100 nM[1]. |
In vivo | PD-1/PD-L1-IN-9 (40-80 mg/kg; p.o. once a day for 2 weeks) inhibits tumor growth in a dose-dependent manner without causing body weight loss or mortality in mice. PD-1/PD-L1-IN-9 (3 mg/kg; a single i.v.) exhibits a half-life (t1/2=4.2 h), plasma clearance (Cl=11.5 L/h/kg), and Cmax (1233 ng/mL) in rats. PD-1/PD-L1-IN-9 (25 mg/kg; a single p.o.) shows moderate oral bioavailability (F=22%), half-life (t1/2=6.4 h), and Cmax (192 ng/mL) in rats[1]. |
Molecular Weight | 348.44 |
Formula | C22H24N2O2 |
Cas No. | 2628506-54-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 90 mg/mL (258.3 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.